These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28087946)

  • 21. Enterococcus faecalis subverts and invades the host urothelium in patients with chronic urinary tract infection.
    Horsley H; Malone-Lee J; Holland D; Tuz M; Hibbert A; Kelsey M; Kupelian A; Rohn JL
    PLoS One; 2013; 8(12):e83637. PubMed ID: 24363814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity.
    Goneau LW; Hannan TJ; MacPhee RA; Schwartz DJ; Macklaim JM; Gloor GB; Razvi H; Reid G; Hultgren SJ; Burton JP
    mBio; 2015 Mar; 6(2):. PubMed ID: 25827417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host-Derived Nitric Oxide and Its Antibacterial Effects in the Urinary Tract.
    Svensson L; Poljakovic M; Demirel I; Sahlberg C; Persson K
    Adv Microb Physiol; 2018; 73():1-62. PubMed ID: 30262107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli.
    Eto DS; Jones TA; Sundsbak JL; Mulvey MA
    PLoS Pathog; 2007 Jul; 3(7):e100. PubMed ID: 17630833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The yin-yang driving urinary tract infection and how proteomics can enhance research, diagnostics, and treatment.
    Floyd KA; Meyer AE; Nelson G; Hadjifrangiskou M
    Proteomics Clin Appl; 2015 Dec; 9(11-12):990-1002. PubMed ID: 26255866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary tract infections-microbial virulence determinants and reactive oxygen species.
    Rama G; Chhina DK; Chhina RS; Sharma S
    Comp Immunol Microbiol Infect Dis; 2005; 28(5-6):339-49. PubMed ID: 16310560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canine bacterial urinary tract infections: new developments in old pathogens.
    Thompson MF; Litster AL; Platell JL; Trott DJ
    Vet J; 2011 Oct; 190(1):22-7. PubMed ID: 21239193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Virulence factors of uropathogens].
    Dobrindt U
    Urologe A; 2010 May; 49(5):598-605. PubMed ID: 20411372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary tract infections: epidemiology, mechanisms of infection and treatment options.
    Flores-Mireles AL; Walker JN; Caparon M; Hultgren SJ
    Nat Rev Microbiol; 2015 May; 13(5):269-84. PubMed ID: 25853778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli.
    Hunstad DA; Justice SS
    Annu Rev Microbiol; 2010; 64():203-21. PubMed ID: 20825346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms.
    Khasriya R; Sathiananthamoorthy S; Ismail S; Kelsey M; Wilson M; Rohn JL; Malone-Lee J
    J Clin Microbiol; 2013 Jul; 51(7):2054-62. PubMed ID: 23596238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bacterial pathogenicity islands].
    Bondarenko VM
    Zh Mikrobiol Epidemiol Immunobiol; 2001; (4):67-74. PubMed ID: 11569271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysregulation of Escherichia coli α-hemolysin expression alters the course of acute and persistent urinary tract infection.
    Nagamatsu K; Hannan TJ; Guest RL; Kostakioti M; Hadjifrangiskou M; Binkley J; Dodson K; Raivio TL; Hultgren SJ
    Proc Natl Acad Sci U S A; 2015 Feb; 112(8):E871-80. PubMed ID: 25675528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strengths and Limitations of Model Systems for the Study of Urinary Tract Infections and Related Pathologies.
    Barber AE; Norton JP; Wiles TJ; Mulvey MA
    Microbiol Mol Biol Rev; 2016 Jun; 80(2):351-67. PubMed ID: 26935136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Urinary tract infections, immunity, and vaccination].
    Luna-Pineda VM; Ochoa S; Cruz-Córdova A; Cázares-Domínguez V; Vélez-González F; Hernández-Castro R; Xicohtencatl-Cortes J
    Bol Med Hosp Infant Mex; 2018; 75(2):67-78. PubMed ID: 29658949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification of Intracellular Bacterial Communities during Experimental Urinary Tract Infection Reveals an Abundant and Viable Bacterial Reservoir.
    Duraiswamy S; Chee JLY; Chen S; Yang E; Lees K; Chen SL
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29378794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility to Urinary Tract Infection: Benefits and Hazards of the Antibacterial Host Response.
    Ambite I; Nagy K; Godaly G; Puthia M; Wullt B; Svanborg C
    Microbiol Spectr; 2016 Jun; 4(3):. PubMed ID: 27337480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative treatment approaches of urinary tract infections caused by uropathogenic Escherichia coli strains.
    Zalewska-Piątek BM; Piątek RJ
    Acta Biochim Pol; 2019 May; 66(2):129-138. PubMed ID: 31136644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages.
    Bokil NJ; Totsika M; Carey AJ; Stacey KJ; Hancock V; Saunders BM; Ravasi T; Ulett GC; Schembri MA; Sweet MJ
    Immunobiology; 2011 Nov; 216(11):1164-71. PubMed ID: 21802164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of bladder glycoprotein GP51 with uropathogenic bacteria.
    Shupp Byrne DE; Sedor JF; Soroush M; McCue PA; Mulholland SG
    J Urol; 2001 Apr; 165(4):1342-6. PubMed ID: 11257713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.